Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.51 |
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | RXRB | P28702 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | FABP7 | O15540 | 1/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21068615 | 0.84 | CES2 (0.46) | FFAR1FFAR4RXRARXRBKMT2A | |
| SCHEMBL5040591 | 0.83 | CA2 (0.56) | IDO1KMT2AMEN1HRH3ALDH1A1 | |
| SCHEMBL21068905 | 0.82 | HRH3 (0.43) | KMT2AHRH3ALDH1A1HPGD | |
| SCHEMBL231282 | 0.81 | TSHR (0.61) | KMT2AALDH1A1MAPT | |
| SCHEMBL30984447 | 0.81 | IDO1 (0.44) | FFAR1FFAR4RXRARXRBIDO1 | |
| SCHEMBL4668893 | 0.81 | FFAR4 (0.49) | FFAR1FFAR4KMT2ASRD5A2MEN1 | |
| SCHEMBL28666321 | 0.81 | FFAR1 (0.57) | FFAR1FFAR4RXRARXRBIDO1 | |
| SCHEMBL13886095 | 0.80 | RAB9A (0.51) | FFAR1MAOBKMT2AHRH3ALDH1A1 | |
| SCHEMBL10151312 | 0.80 | RXRA (0.50) | RXRARXRBIDO1HRH3ALDH1A1 | |
| SCHEMBL360819 | 0.80 | NR4A2 (0.50) | FFAR1IDO1MAOBFABP7FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 379 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114362762-B | LZSS bridge data compression parallel method, system, medium and equipment based on FPGA | 西安交通大学 | 2025-05-16 | — | — | CN | claimed |
| WO-2025055211-A1 | METHOD FOR PREPARING PEROVSKITE SOLAR CELL, AND PEROVSKITE SOLAR CELL | 中国科学院深圳先进技术研究院 | 2025-03-20 | — | — | WO | claimed |
| CN-221861945-U | High-gain wide-band omnidirectional antenna unit and antenna array thereof | 上海电连旭晟通信技术有限公司 | 2024-10-18 | — | — | CN | claimed |
| CN-117919576-A | Thickness-controllable medicine applicator | 上海市宝山区仁和医院 | 2024-04-26 | — | — | CN | claimed |
| EP-4144845-B1 | ANTISENSE COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS INC (US) | 2024-04-24 | — | — | EP | claimed |
| CN-117119816-A | Perovskite solar cell and preparation method thereof | 中国科学院深圳先进技术研究院 | 2023-11-24 | — | — | CN | claimed |
| EP-4144845-A1 | ANTISENSE COMPOUNDS AND USES THEREOF | Ionis Pharmaceuticals, Inc. (US) | 2023-03-08 | — | — | EP | claimed |
| EP-2906255-B1 | ANTISENSE COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS INC (US) | 2023-02-22 | — | — | EP | claimed |
| CN-114362762-A | LZSS bridge data compression parallel method, system, medium and equipment based on FPGA | 西安交通大学 | 2022-04-15 | — | — | CN | claimed |
| US-5679777-A | TIME-RELEASE AGENTS COMPRISING CONJUGATES OF GENETICALLY ENGINEERED PROTEINS AS DRUG CARRIERS; ENHANCED STABILITY; INCREASED VASCULAR RETENTION | SOMATOGEN, INC. (US) | 1997-10-21 | — | — | US | claimed |
| US-4482571-A | BENZYLOXY ACIDS | UNIVERSITY OF PITTSBURGH (US) | 1984-11-13 | — | — | US | claimed |
| US-20260146064-A1 | PH-SENSITIVE MEMBRANE DISRUPTIVE PEPTIDES AND USE THEREOF | SOUTH CHINA UNIVERSITY OF TECHNOLOGY (CN) | 2026-05-28 | — | — | US | disclosed |
| US-20260145446-A1 | DUPLEX PRINTING SYSTEM FOR A CARD PERSONALIZATION SYSTEM | Entrust Corporation (US) | 2026-05-28 | — | — | US | disclosed |
| CN-115391184-B | AB test method, device and equipment | BEIJING BAIDU NETCOM SCIENCE AND TECHNOLOGY CO.,LTD. (CN) | 2026-05-26 | — | — | CN | disclosed |
| US-20260139014-A1 | CHIMERIC NEUROTOXINS | IPSEN BIOPHARM LTD (GB) | 2026-05-21 | — | — | US | disclosed |
| US-4731473-A | Compounds useful in treating sickle cell anemia | MERCK & CO., INC. (US) | 1988-03-15 | — | — | US | disclosed |
| US-4699926-A | Compounds useful in treating sickle cell anemia | MERCK & CO., INC. (US) | 1987-10-13 | — | — | US | disclosed |
| EP-0240256-A2 | Compounds useful in treating sickle cell anemia | MERCK & CO. INC. (US) | 1987-10-07 | — | — | EP | disclosed |
| US-4482571-A | BENZYLOXY ACIDS | UNIVERSITY OF PITTSBURGH (US) | 1984-11-13 | — | — | US | disclosed |
| US-4482571-A | BENZYLOXY ACIDS | UNIVERSITY OF PITTSBURGH (US) | 1984-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260145446-A1 | DUPLEX PRINTING SYSTEM FOR A CARD PERSONALIZATION SYSTEM | DDX42, PDE11A, CARD19 | FFAR1 2430/4885FFAR4 1336/4885RXRA 2450/4885 |
| US-20260146064-A1 | PH-SENSITIVE MEMBRANE DISRUPTIVE PEPTIDES AND USE THEREOF | LNPK, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, YWHAZ | FFAR1 1639/4885FFAR4 2338/4885RXRA 3381/4885 |
| US-20260139014-A1 | CHIMERIC NEUROTOXINS | CHRNA7, CHRND, CHRNA5 | FFAR1 2871/4885FFAR4 1906/4885RXRA 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.